ASX:PCK

PainChek Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive PCK News and Ratings via Email

Sign-up to receive the latest news and ratings for PainChek and its competitors with MarketBeat's FREE daily newsletter.

About PainChek

PainChek Limited develops and commercializes mobile medical device applications that provides pain assessment for individuals primarily in Australia and Europe. The company offers PainChek, which uses camera in smartphone and tablets to capture video that is analyzed in real time using facial recognition software to indicate the presence of the pain. It serves patients suffering with dementia. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited. in January 2018. PainChek Limited is based in Sydney, Australia.

Total Brain Limited (TTB.AX)
July 23, 2021 | au.finance.yahoo.com

Market Sentiment Around Loss-Making PainChek Limited (ASX:PCK)
May 31, 2021 | finance.yahoo.com

The PainChek (ASX:PCK) share price is rising on its latest announcement
May 20, 2021 | msn.com

Why the Painchek (ASX:PCK) share price is charging 13% higher
March 17, 2021 | msn.com

We're Not Worried About PainChek's (ASX:PCK) Cash Burn
March 2, 2021 | finance.yahoo.com

Why the Painchek (ASX:PCK) share price is edging higher today
February 26, 2021 | msn.com

We're Not Very Worried About PainChek's (ASX:PCK) Cash Burn Rate
December 14, 2020 | finance.yahoo.com

When Will PainChek Ltd. (ASX:PCK) Become Profitable?
December 14, 2020 | finance.yahoo.com

Investors Who Bought PainChek (ASX:PCK) Shares A Year Ago Are Now Up 92%
December 14, 2020 | finance.yahoo.com

PainChek Limited (ASX:PCK) Is Expected To Breakeven In The Near Future
December 14, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange ASX
Industry Health Information Services
Sub-IndustryN/A
SectorMedical
Current SymbolASX:PCK
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.painchek.com
Phone1800 098 809
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$240,424.00
Price / Sales0.00
Cash FlowN/A
Price / Cash FlowN/A
Book ValueA$0.01 per share
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for PainChek.

0.0 Community Rank

Outperform Votes
PainChek has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
PainChek has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about PainChek and other stocks. Vote “Outperform” if you believe PCK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PCK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
PainChek does not currently pay a dividend.
Dividend Growth
PainChek does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PainChek insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

PainChek (ASX:PCK) Frequently Asked Questions

What stocks does MarketBeat like better than PainChek?

Wall Street analysts have given PainChek a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PainChek wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are PainChek's key executives?

PainChek's management team includes the following people:

Mr. Philip Daffas B.Sc., M.B.A., BSc, Dip EENG, MBA, GAICD, MD, CEO & Director
Mr. Iain McAdam, Chief Financial Officer
Mr. Andrew Hoggan, Head of Operations
Mr. Scott Robertson M.B.A., Chief Technology Officer
Prof. Jeff Hughes Ph.D., Chief Scientific Officer
Mr. David Allsopp, Head of Bus. Devel. ANZ
Mr. Pete Shergill, Head of Bus. Devel. UK
Ms. Sally McDow, Company Sec.

Who are some of PainChek's key competitors?

Some companies that are related to PainChek include 1st Group (1ST), Alcidion Group (ALC), Binovi Technologies (BNVIF), Cann American (CNNA), Carebook Technologies (CRBKF), CloudMD Software & Services (DOCRF), Cogstate (CGS), Corum Group (COO), EGF Theramed Health (EVAHF), Emyria (EMD), eWellness Healthcare (EWLL), Global Health (GLH), ICS Global (ICS), Intelicare (ICR) and Jayex Healthcare (JHL).
View all of PCK's competitors.

What is PainChek's stock symbol?

PainChek trades on the ASX under the ticker symbol "PCK."

How much money does PainChek make?

PainChek has a market capitalization of $0.00 and generates $240,424.00 in revenue each year.

What is PainChek's official website?

The official website for PainChek is www.painchek.com.

How can I contact PainChek?

The company can be reached via phone at 1800 098 809.

This page was last updated on 7/30/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.